Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT)

Baird Financial Group Inc. bought a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 59,440 shares of the company’s stock, valued at approximately $429,000. Baird Financial Group Inc. owned 0.08% of Altimmune as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wells Fargo & Company MN grew its position in shares of Altimmune by 69.3% during the 4th quarter. Wells Fargo & Company MN now owns 215,538 shares of the company’s stock valued at $1,554,000 after acquiring an additional 88,209 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Altimmune during the 4th quarter valued at approximately $45,000. Marshall Wace LLP bought a new position in shares of Altimmune during the 4th quarter valued at approximately $472,000. Bellevue Group AG lifted its stake in shares of Altimmune by 9.5% during the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock valued at $6,817,000 after buying an additional 81,786 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Altimmune by 679.2% during the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company’s stock valued at $1,781,000 after buying an additional 215,375 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Price Performance

NASDAQ ALT opened at $5.78 on Friday. Altimmune, Inc. has a 1 year low of $3.55 and a 1 year high of $11.16. The stock has a market capitalization of $445.14 million, a PE ratio of -3.73 and a beta of 1.13. The company’s 50 day simple moving average is $5.10 and its two-hundred day simple moving average is $6.58.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.09. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. During the same period in the prior year, the company posted ($0.34) EPS. On average, research analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on ALT shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Thursday, April 3rd. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $20.20.

Insiders Place Their Bets

In other news, CFO Gregory L. Weaver bought 10,000 shares of the stock in a transaction on Thursday, March 13th. The shares were acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.